Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NST0078
- Development stage
- Preclinical
- Lead developer
- Neuron Biopharma
- Modality
- Small Molecules
01
Overview
NST0078 is a small molecule drug candidate developed by Neuron Bio for the treatment of Mild Cognitive Impairment (MCI). Developed within the company's neuropharma division, the compound is part of a pipeline focused on neurodegenerative and central nervous system disorders. As of the available data, NST0078 has progressed through preclinical screening and efficacy stages and is moving toward regulatory-enabling studies. The specific molecular target and mechanism of action for NST0078 have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on NST0078.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NST0078.